423 related articles for article (PubMed ID: 31594388)
1. Targeting AKT for cancer therapy.
Shariati M; Meric-Bernstam F
Expert Opin Investig Drugs; 2019 Nov; 28(11):977-988. PubMed ID: 31594388
[No Abstract] [Full Text] [Related]
2. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
3. Targeting the PI3K/AKT signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020-2023).
Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
Expert Opin Ther Pat; 2024 Mar; 34(3):141-158. PubMed ID: 38557273
[TBL] [Abstract][Full Text] [Related]
4. Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer.
Hernandez-Aya LF; Gonzalez-Angulo AM
Oncologist; 2011; 16(4):404-14. PubMed ID: 21406469
[TBL] [Abstract][Full Text] [Related]
5. Modulation of cell sensitivity to antitumor agents by targeting survival pathways.
Perego P; Cossa G; Zuco V; Zunino F
Biochem Pharmacol; 2010 Nov; 80(10):1459-65. PubMed ID: 20688050
[TBL] [Abstract][Full Text] [Related]
6. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.
Martelli AM; Evangelisti C; Chiarini F; McCubrey JA
Oncotarget; 2010 Jun; 1(2):89-103. PubMed ID: 20671809
[TBL] [Abstract][Full Text] [Related]
7. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.
Burris HA
Cancer Chemother Pharmacol; 2013 Apr; 71(4):829-42. PubMed ID: 23377372
[TBL] [Abstract][Full Text] [Related]
8. Targeting the Akt kinase to modulate survival, invasiveness and drug resistance of cancer cells.
Cassinelli G; Zuco V; Gatti L; Lanzi C; Zaffaroni N; Colombo D; Perego P
Curr Med Chem; 2013; 20(15):1923-45. PubMed ID: 23410153
[TBL] [Abstract][Full Text] [Related]
9. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside.
Martelli AM; Tazzari PL; Evangelisti C; Chiarini F; Blalock WL; Billi AM; Manzoli L; McCubrey JA; Cocco L
Curr Med Chem; 2007; 14(19):2009-23. PubMed ID: 17691943
[TBL] [Abstract][Full Text] [Related]
10. New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer.
Sun Z; Wang Z; Liu X; Wang D
Anticancer Drugs; 2015 Jan; 26(1):1-14. PubMed ID: 25304988
[TBL] [Abstract][Full Text] [Related]
11. Targeting the PI3K/Akt/mTOR pathway in malignancy: rationale and clinical outlook.
Cho DC
BioDrugs; 2014 Aug; 28(4):373-81. PubMed ID: 24567265
[TBL] [Abstract][Full Text] [Related]
12. Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT.
O'Brien NA; McDonald K; Tong L; von Euw E; Kalous O; Conklin D; Hurvitz SA; di Tomaso E; Schnell C; Linnartz R; Finn RS; Hirawat S; Slamon DJ
Clin Cancer Res; 2014 Jul; 20(13):3507-20. PubMed ID: 24879796
[TBL] [Abstract][Full Text] [Related]
13. Targeting AKT/PKB to improve treatment outcomes for solid tumors.
Iida M; Harari PM; Wheeler DL; Toulany M
Mutat Res; 2020; 819-820():111690. PubMed ID: 32120136
[TBL] [Abstract][Full Text] [Related]
14. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.
Hirai H; Sootome H; Nakatsuru Y; Miyama K; Taguchi S; Tsujioka K; Ueno Y; Hatch H; Majumder PK; Pan BS; Kotani H
Mol Cancer Ther; 2010 Jul; 9(7):1956-67. PubMed ID: 20571069
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy.
Chen YL; Law PY; Loh HH
Curr Med Chem Anticancer Agents; 2005 Nov; 5(6):575-89. PubMed ID: 16305480
[TBL] [Abstract][Full Text] [Related]
16. Targeting the PI3K-AKT-mTOR signaling network in cancer.
Khan KH; Yap TA; Yan L; Cunningham D
Chin J Cancer; 2013 May; 32(5):253-65. PubMed ID: 23642907
[TBL] [Abstract][Full Text] [Related]
17. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer.
Fumarola C; Bonelli MA; Petronini PG; Alfieri RR
Biochem Pharmacol; 2014 Aug; 90(3):197-207. PubMed ID: 24863259
[TBL] [Abstract][Full Text] [Related]
18. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
[TBL] [Abstract][Full Text] [Related]
19. Maximising the potential of AKT inhibitors as anti-cancer treatments.
Brown JS; Banerji U
Pharmacol Ther; 2017 Apr; 172():101-115. PubMed ID: 27919797
[TBL] [Abstract][Full Text] [Related]
20. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R; O'Regan RM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]